ロード中...
ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry
Host cell proteins (HCPs) must be adequately removed from recombinant therapeutics by downstream processing to ensure patient safety, product quality, and regulatory compliance. HCP process clearance is typically monitored by enzyme-linked immunosorbent assay (ELISA) using a polyclonal reagent. Rece...
保存先:
| 出版年: | MAbs |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5627587/ https://ncbi.nlm.nih.gov/pubmed/28708446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1349586 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|